PUBLIC COMPANY
save$SANASana Biotechnology, Inc.
$SANA1.88000.00%Seattle, WA, USupdated 1d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
5
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Preclinical
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
🐶 Hiring Signal
Where Sana Biotechnology, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaMetabolic 2
News
- After GLP-1s, biosimilars are the new frontier in direct-to-employer plansFresenius Kabi will sell biosimilars directly to employers. To accomplish that, the drugmaker is working with Eversana-owned Waltz Health, which runs a marketplace that helps employers shop for bet…endpoints · 1mo ago
- As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safetyAs the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously…fiercebiotech · 2mo ago
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independenceAfter the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…biospace · 4mo ago
- Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storyAn oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.stat · 5mo ago
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that